ID   FOXP3_HUMAN             Reviewed;         431 AA.
AC   Q9BZS1; A5HJT1; B7ZLG0; B9UN80; O60827; Q14DD8; Q4ZH51;
DT   20-JUN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   05-JUL-2017, entry version 173.
DE   RecName: Full=Forkhead box protein P3;
DE   AltName: Full=Scurfin;
DE   Contains:
DE     RecName: Full=Forkhead box protein P3, C-terminally processed;
DE   Contains:
DE     RecName: Full=Forkhead box protein P3 41 kDa form;
GN   Name=FOXP3; Synonyms=IPEX; ORFNames=JM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=11138001; DOI=10.1038/83784;
RA   Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B.,
RA   Yasayko S.-A., Wilkinson J.E., Galas D., Ziegler S.F., Ramsdell F.;
RT   "Disruption of a new forkhead/winged-helix protein, scurfin, results
RT   in the fatal lymphoproliferative disorder of the scurfy mouse.";
RL   Nat. Genet. 27:68-73(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Wang J., Liu Q., Zhang Y., Xu Z., Huang C.;
RT   "Cloning and expression of the cDNA for FOXP3.";
RL   Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RA   Kaur G., Goodall J.C., Jarvis L.B., Gaston J.S.H.;
RT   "Functional characterization of FOXP3 splice variants in human
RT   regulatory T cells.";
RL   Submitted (JUN-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Lin L., Nong W., Li H., Ke R., Shen C., Zhong G., Zheng Z., Liang M.,
RA   Huang B., Zhou G., Yang S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 16-431 (ISOFORM 3).
RA   Strom T.M., Nyakatura G., Hellebrand H., Drescher B., Rosenthal A.,
RA   Meindl A.;
RT   "Transcription map in Xp11.23.";
RL   Submitted (APR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   FUNCTION, AND INTERACTION WITH RELA AND NFATC2.
RX   PubMed=15790681; DOI=10.1073/pnas.0501675102;
RA   Bettelli E., Dastrange M., Oukka M.;
RT   "Foxp3 interacts with nuclear factor of activated T cells and NF-kappa
RT   B to repress cytokine gene expression and effector functions of T
RT   helper cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:5138-5143(2005).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH RUNX1.
RX   PubMed=17377532; DOI=10.1038/nature05673;
RA   Ono M., Yaguchi H., Ohkura N., Kitabayashi I., Nagamura Y., Nomura T.,
RA   Miyachi Y., Tsukada T., Sakaguchi S.;
RT   "Foxp3 controls regulatory T-cell function by interacting with
RT   AML1/Runx1.";
RL   Nature 446:685-689(2007).
RN   [10]
RP   FUNCTION, ACETYLATION, INTERACTION WITH KAT5; HDAC7 AND HDAC9, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=17360565; DOI=10.1073/pnas.0700298104;
RA   Li B., Samanta A., Song X., Iacono K.T., Bembas K., Tao R., Basu S.,
RA   Riley J.L., Hancock W.W., Shen Y., Saouaf S.J., Greene M.I.;
RT   "FOXP3 interactions with histone acetyltransferase and class II
RT   histone deacetylases are required for repression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:4571-4576(2007).
RN   [11]
RP   FUNCTION, INTERACTION WITH RORA, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF 95-LEU-LEU-96.
RX   PubMed=18354202; DOI=10.4049/jimmunol.180.7.4785;
RA   Du J., Huang C., Zhou B., Ziegler S.F.;
RT   "Isoform-specific inhibition of ROR alpha-mediated transcriptional
RT   activation by human FOXP3.";
RL   J. Immunol. 180:4785-4792(2008).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH RORC.
RX   PubMed=18368049; DOI=10.1038/nature06878;
RA   Zhou L., Lopes J.E., Chong M.M., Ivanov I.I., Min R., Victora G.D.,
RA   Shen Y., Du J., Rubtsov Y.P., Rudensky A.Y., Ziegler S.F.,
RA   Littman D.R.;
RT   "TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by
RT   antagonizing RORgammat function.";
RL   Nature 453:236-240(2008).
RN   [13]
RP   PROTEOLYTIC PROCESSING.
RX   PubMed=19117830; DOI=10.1074/jbc.M807322200;
RA   de Zoeten E.F., Lee I., Wang L., Chen C., Ge G., Wells A.D.,
RA   Hancock W.W., Ozkaynak E.;
RT   "Foxp3 processing by proprotein convertases and control of regulatory
RT   T cell function.";
RL   J. Biol. Chem. 284:5709-5716(2009).
RN   [14]
RP   INTERACTION WITH IKZF3.
RX   PubMed=20676092; DOI=10.1038/ni.1915;
RA   Gandhi R., Kumar D., Burns E.J., Nadeau M., Dake B., Laroni A.,
RA   Kozoriz D., Weiner H.L., Quintana F.J.;
RT   "Activation of the aryl hydrocarbon receptor induces human type 1
RT   regulatory T cell-like and Foxp3(+) regulatory T cells.";
RL   Nat. Immunol. 11:846-853(2010).
RN   [15]
RP   SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, NUCLEAR EXPORT
RP   SIGNAL, AND MUTAGENESIS OF LEU-69; LEU-71; LEU-74; LEU-76;
RP   415-LYS-LYS-416; LEU-242; LEU-246 AND LEU-248.
RX   PubMed=22678915; DOI=10.1002/eji.201141838;
RA   Magg T., Mannert J., Ellwart J.W., Schmid I., Albert M.H.;
RT   "Subcellular localization of FOXP3 in human regulatory and
RT   nonregulatory T cells.";
RL   Eur. J. Immunol. 42:1627-1638(2012).
RN   [16]
RP   ACETYLATION AT LYS-31; LYS-263 AND LYS-268, AND DEACETYLATION BY
RP   SIRT1.
RX   PubMed=22312127; DOI=10.4049/jimmunol.1100903;
RA   Kwon H.S., Lim H.W., Wu J., Schnolzer M., Verdin E., Ott M.;
RT   "Three novel acetylation sites in the Foxp3 transcription factor
RT   regulate the suppressive activity of regulatory T cells.";
RL   J. Immunol. 188:2712-2721(2012).
RN   [17]
RP   FUNCTION.
RX   PubMed=23169781; DOI=10.1182/blood-2012-05-431023;
RA   McMurchy A.N., Gillies J., Gizzi M.C., Riba M., Garcia-Manteiga J.M.,
RA   Cittaro D., Lazarevic D., Di Nunzio S., Piras I.S., Bulfone A.,
RA   Roncarolo M.G., Stupka E., Bacchetta R., Levings M.K.;
RT   "A novel function for FOXP3 in humans: intrinsic regulation of
RT   conventional T cells.";
RL   Blood 121:1265-1275(2013).
RN   [18]
RP   REVIEW.
RX   PubMed=24350059; DOI=10.3389/fonc.2013.00294;
RA   Lozano T., Casares N., Lasarte J.J.;
RT   "Searching for the Achilles Heel of FOXP3.";
RL   Front. Oncol. 3:294-294(2013).
RN   [19]
RP   UBIQUITINATION, DEUBIQUITINATION, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH USP7.
RX   PubMed=23973222; DOI=10.1016/j.immuni.2013.05.018;
RA   van Loosdregt J., Fleskens V., Fu J., Brenkman A.B., Bekker C.P.,
RA   Pals C.E., Meerding J., Berkers C.R., Barbi J., Grone A., Sijts A.J.,
RA   Maurice M.M., Kalkhoven E., Prakken B.J., Ovaa H., Pan F., Zaiss D.M.,
RA   Coffer P.J.;
RT   "Stabilization of the transcription factor Foxp3 by the deubiquitinase
RT   USP7 increases Treg-cell-suppressive capacity.";
RL   Immunity 39:259-271(2013).
RN   [20]
RP   INTERACTION WITH STUB1; HSPA8 AND HSPA1A/B, SUBCELLULAR LOCATION,
RP   UBIQUITINATION, AND INDUCTION.
RX   PubMed=23973223; DOI=10.1016/j.immuni.2013.08.006;
RA   Chen Z., Barbi J., Bu S., Yang H.Y., Li Z., Gao Y., Jinasena D.,
RA   Fu J., Lin F., Chen C., Zhang J., Yu N., Li X., Shan Z., Nie J.,
RA   Gao Z., Tian H., Li Y., Yao Z., Zheng Y., Park B.V., Pan Z., Zhang J.,
RA   Dang E., Li Z., Wang H., Luo W., Li L., Semenza G.L., Zheng S.G.,
RA   Loser K., Tsun A., Greene M.I., Pardoll D.M., Pan F., Li B.;
RT   "The ubiquitin ligase Stub1 negatively modulates regulatory T cell
RT   suppressive activity by promoting degradation of the transcription
RT   factor Foxp3.";
RL   Immunity 39:272-285(2013).
RN   [21]
RP   INTERACTION WITH ZFP90.
RX   PubMed=23543754; DOI=10.4049/jimmunol.1203561;
RA   Huang C., Martin S., Pfleger C., Du J., Buckner J.H., Bluestone J.A.,
RA   Riley J.L., Ziegler S.F.;
RT   "Cutting Edge: a novel, human-specific interacting protein couples
RT   FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28.";
RL   J. Immunol. 190:4470-4473(2013).
RN   [22]
RP   PHOSPHORYLATION AT SER-418, SUBCELLULAR LOCATION, INTERACTION WITH
RP   PPP1CA; PPP1CB AND PPP1CG, MUTAGENESIS OF SER-418 AND SER-422, AND
RP   DEPHOSPHORYLATION.
RX   PubMed=23396208; DOI=10.1038/nm.3085;
RA   Nie H., Zheng Y., Li R., Guo T.B., He D., Fang L., Liu X., Xiao L.,
RA   Chen X., Wan B., Chin Y.E., Zhang J.Z.;
RT   "Phosphorylation of FOXP3 controls regulatory T cell function and is
RT   inhibited by TNF-alpha in rheumatoid arthritis.";
RL   Nat. Med. 19:322-328(2013).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=23947341; DOI=10.3109/08830185.2013.811657;
RA   Vent-Schmidt J., Han J.M., MacDonald K.G., Levings M.K.;
RT   "The role of FOXP3 in regulating immune responses.";
RL   Int. Rev. Immunol. 33:110-128(2014).
RN   [24]
RP   REVIEW ON FUNCTION.
RX   PubMed=24354325; DOI=10.3109/08830185.2013.863303;
RA   Passerini L., Santoni de Sio F.R., Roncarolo M.G., Bacchetta R.;
RT   "Forkhead box P3: the peacekeeper of the immune system.";
RL   Int. Rev. Immunol. 33:129-145(2014).
RN   [25]
RP   REVIEW.
RX   PubMed=24722479; DOI=10.1038/nri3650;
RA   Ramsdell F., Ziegler S.F.;
RT   "FOXP3 and scurfy: how it all began.";
RL   Nat. Rev. Immunol. 14:343-349(2014).
RN   [26]
RP   REVIEW ON PTM.
RX   PubMed=25047417; DOI=10.1016/j.it.2014.06.005;
RA   van Loosdregt J., Coffer P.J.;
RT   "Post-translational modification networks regulating FOXP3 function.";
RL   Trends Immunol. 35:368-378(2014).
RN   [27]
RP   VARIANT IPEX GLU-251 DEL.
RX   PubMed=11120765; DOI=10.1172/JCI11679;
RA   Chatila T.A., Blaeser F., Ho N., Lederman H.M., Voulgaropoulos C.,
RA   Helms C., Bowcock A.M.;
RT   "JM2, encoding a fork head-related protein, is mutated in X-linked
RT   autoimmunity-allergic disregulation syndrome.";
RL   J. Clin. Invest. 106:R75-R81(2000).
RN   [28]
RP   VARIANT IPEX VAL-363.
RX   PubMed=11768393; DOI=10.1136/jmg.38.12.874;
RA   Kobayashi I., Shiari R., Yamada M., Kawamura N., Okano M., Yara A.,
RA   Iguchi A., Ishikawa N., Ariga T., Sakiyama Y., Ochs H.D.,
RA   Kobayashi K.;
RT   "Novel mutations of FOXP3 in two Japanese patients with immune
RT   dysregulation, polyendocrinopathy, enteropathy, X linked syndrome
RT   (IPEX).";
RL   J. Med. Genet. 38:874-876(2001).
RN   [29]
RP   VARIANTS IPEX CYS-371; THR-384 AND TRP-397.
RX   PubMed=11137992; DOI=10.1038/83707;
RA   Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.-L.,
RA   Buist N., Levy-Lahad E., Mazzella M., Goulet O., Perroni L.,
RA   Bricarelli F.D., Byrne G., McEuen M., Proll S., Appleby M.,
RA   Brunkow M.E.;
RT   "X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy
RT   syndrome is the human equivalent of mouse scurfy.";
RL   Nat. Genet. 27:18-20(2001).
RN   [30]
RP   VARIANT IPEX THR-384.
RX   PubMed=11137993; DOI=10.1038/83713;
RA   Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J.,
RA   Whitesell L., Kelly T.E., Saulsbury F.T., Chance P.F., Ochs H.D.;
RT   "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked
RT   syndrome (IPEX) is caused by mutations of FOXP3.";
RL   Nat. Genet. 27:20-21(2001).
CC   -!- FUNCTION: Transcriptional regulator which is crucial for the
CC       development and inhibitory function of regulatory T-cells (Treg).
CC       Plays an essential role in maintaining homeostasis of the immune
CC       system by allowing the acquisition of full suppressive function
CC       and stability of the Treg lineage, and by directly modulating the
CC       expansion and function of conventional T-cells. Can act either as
CC       a transcriptional repressor or a transcriptional activator
CC       depending on its interactions with other transcription factors,
CC       histone acetylases and deacetylases. The suppressive activity of
CC       Treg involves the coordinate activation of many genes, including
CC       CTLA4 and TNFRSF18 by FOXP3 along with repression of genes
CC       encoding cytokines such as interleukin-2 (IL2) and interferon-
CC       gamma (IFNG). Inhibits cytokine production and T-cell effector
CC       function by repressing the activity of two key transcription
CC       factors, RELA and NFATC2 (PubMed:15790681). Mediates
CC       transcriptional repression of IL2 via its association with histone
CC       acetylase KAT5 and histone deacetylase HDAC7 (PubMed:17360565).
CC       Can activate the expression of TNFRSF18, IL2RA and CTLA4 and
CC       repress the expression of IL2 and IFNG via its association with
CC       transcription factor RUNX1 (PubMed:17377532). Inhibits the
CC       differentiation of IL17 producing helper T-cells (Th17) by
CC       antagonizing RORC function, leading to down-regulation of IL17
CC       expression, favoring Treg development (PubMed:18368049). Inhibits
CC       the transcriptional activator activity of RORA (PubMed:18354202).
CC       Can repress the expression of IL2 and IFNG via its association
CC       with transcription factor IKZF4 (By similarity).
CC       {ECO:0000250|UniProtKB:Q99JB6, ECO:0000269|PubMed:15790681,
CC       ECO:0000269|PubMed:17360565, ECO:0000269|PubMed:17377532,
CC       ECO:0000269|PubMed:18354202, ECO:0000269|PubMed:18368049,
CC       ECO:0000269|PubMed:23169781}.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with IKZF3. Isoform
CC       1 (via LXXLL motif), but not isoform 2, interacts with isoform 4
CC       of RORA (via AF-2 motif). Interacts with STUB1, HSPA8 and
CC       HSPA1A/B. Interacts with PPP1CA, PPP1CB and PPP1CG. Interacts with
CC       KAT5 and HDAC7. Interacts with HDAC9 in the absence of T-cell
CC       stimulation. Interacts with USP7. Interacts with isoform 2 of
CC       ZFP90 and can form a complex with TRIM28 in the presence of
CC       isoform 2 of ZFP90. Interacts with RUNX1. Interacts with RORC.
CC       Interacts with RELA and NFATC2. Interacts with RUNX2, RUNX3 and
CC       IKZF4 (By similarity). {ECO:0000250|UniProtKB:Q99JB6,
CC       ECO:0000269|PubMed:15790681, ECO:0000269|PubMed:17360565,
CC       ECO:0000269|PubMed:17377532, ECO:0000269|PubMed:18354202,
CC       ECO:0000269|PubMed:18368049, ECO:0000269|PubMed:20676092,
CC       ECO:0000269|PubMed:23396208, ECO:0000269|PubMed:23543754,
CC       ECO:0000269|PubMed:23973222, ECO:0000269|PubMed:23973223}.
CC   -!- INTERACTION:
CC       Q8WUI4:HDAC7; NbExp=2; IntAct=EBI-9695448, EBI-1048378;
CC       Q9UKT9:IKZF3; NbExp=2; IntAct=EBI-983719, EBI-747204;
CC       Q92993:KAT5; NbExp=2; IntAct=EBI-9695448, EBI-399080;
CC       P11309-2:PIM1; NbExp=3; IntAct=EBI-9695448, EBI-1018633;
CC       P62136:PPP1CA; NbExp=2; IntAct=EBI-983719, EBI-357253;
CC       P86479:PRR20C; NbExp=4; IntAct=EBI-983719, EBI-10172814;
CC       P86478:PRR20E; NbExp=3; IntAct=EBI-983719, EBI-12700196;
CC       Q93062:RBPMS; NbExp=4; IntAct=EBI-983719, EBI-740322;
CC       Q93062-3:RBPMS; NbExp=3; IntAct=EBI-983719, EBI-740343;
CC       P35398-4:RORA; NbExp=5; IntAct=EBI-983719, EBI-11295807;
CC       Q9UNE7:STUB1; NbExp=7; IntAct=EBI-983719, EBI-357085;
CC       Q8TF47-3:ZFP90; NbExp=4; IntAct=EBI-983719, EBI-11419904;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-
CC       ProRule:PRU00089, ECO:0000269|PubMed:17360565,
CC       ECO:0000269|PubMed:18354202, ECO:0000269|PubMed:22678915,
CC       ECO:0000269|PubMed:23396208, ECO:0000269|PubMed:23973222,
CC       ECO:0000269|PubMed:23973223}. Cytoplasm
CC       {ECO:0000269|PubMed:22678915}. Note=Predominantly expressed in the
CC       cytoplasm in activated conventional T-cells whereas predominantly
CC       expressed in the nucleus in regulatory T-cells (Treg). The 41 kDa
CC       form derived by proteolytic processing is found exclusively in the
CC       chromatin fraction of activated Treg cells (By similarity).
CC       {ECO:0000250|UniProtKB:Q99JB6, ECO:0000269|PubMed:22678915}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9BZS1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BZS1-2; Sequence=VSP_015796;
CC       Name=3;
CC         IsoId=Q9BZS1-3; Sequence=VSP_015796, VSP_036418;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=Q9BZS1-4; Sequence=VSP_047859;
CC   -!- INDUCTION: Down-regulated in regulatory T-cells (Treg) during
CC       inflammation. {ECO:0000269|PubMed:23973223}.
CC   -!- PTM: Polyubiquitinated, leading to its proteasomal degradation in
CC       regulatory T-cells (Treg) which is mediated by STUB1 in a
CC       HSPA1A/B-dependent manner. Deubiquitinated by USP7 leading to
CC       increase in protein stability. {ECO:0000269|PubMed:23973222,
CC       ECO:0000269|PubMed:23973223}.
CC   -!- PTM: Phosphorylation at Ser-418 regulates its transcriptional
CC       repressor activity and consequently, regulatory T-cells (Treg)
CC       suppressive function. Dephosphorylated at Ser-418 by protein
CC       phosphatase 1 (PP1) in Treg cells derived from patients with
CC       rheumatoid arthritis. Phosphorylation by CDK2 negatively regulates
CC       its transcriptional activity and protein stability (By
CC       similarity). {ECO:0000250|UniProtKB:Q99JB6,
CC       ECO:0000269|PubMed:23396208}.
CC   -!- PTM: Acetylation on lysine residues stabilizes FOXP3 and promotes
CC       differentiation of T-cells into induced regulatory T-cells
CC       (iTregs) associated with suppressive functions. Deacetylated by
CC       SIRT1. {ECO:0000269|PubMed:17360565, ECO:0000269|PubMed:22312127}.
CC   -!- PTM: Undergoes proteolytic cleavage in activated regulatory T-
CC       cells (Treg), and can be cleaved at either the N- or C-terminal
CC       site, or at both sites. {ECO:0000269|PubMed:19117830}.
CC   -!- DISEASE: Immunodeficiency polyendocrinopathy, enteropathy, X-
CC       linked syndrome (IPEX) [MIM:304790]: Characterized by neonatal
CC       onset insulin-dependent diabetes mellitus, infections, secretory
CC       diarrhea, thrombocytopenia, anemia and eczema. It is usually
CC       lethal in infancy. {ECO:0000269|PubMed:11120765,
CC       ECO:0000269|PubMed:11137992, ECO:0000269|PubMed:11137993,
CC       ECO:0000269|PubMed:11768393}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FOXP3ID44129chXp11.html";
CC   -!- WEB RESOURCE: Name=FOXP3base; Note=FOXP3 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/FOXP3base/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=FOXP3 entry;
CC       URL="https://en.wikipedia.org/wiki/FOXP3";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF277993; AAG53607.1; -; mRNA.
DR   EMBL; EF534714; ABQ15210.1; -; mRNA.
DR   EMBL; EU855812; ACJ46653.1; -; mRNA.
DR   EMBL; DQ010327; AAY27088.1; -; mRNA.
DR   EMBL; AF235097; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC113401; AAI13402.1; -; mRNA.
DR   EMBL; BC113403; AAI13404.1; -; mRNA.
DR   EMBL; BC143785; AAI43786.1; -; mRNA.
DR   EMBL; AJ005891; CAA06748.1; -; mRNA.
DR   CCDS; CCDS14323.1; -. [Q9BZS1-1]
DR   CCDS; CCDS48109.1; -. [Q9BZS1-2]
DR   RefSeq; NP_001107849.1; NM_001114377.1. [Q9BZS1-2]
DR   RefSeq; NP_054728.2; NM_014009.3. [Q9BZS1-1]
DR   UniGene; Hs.247700; -.
DR   PDB; 3QRF; X-ray; 2.80 A; F/G/H/I=336-417.
DR   PDB; 4WK8; X-ray; 3.40 A; F/G=336-417.
DR   PDBsum; 3QRF; -.
DR   PDBsum; 4WK8; -.
DR   ProteinModelPortal; Q9BZS1; -.
DR   SMR; Q9BZS1; -.
DR   BioGrid; 119170; 70.
DR   DIP; DIP-36584N; -.
DR   IntAct; Q9BZS1; 68.
DR   STRING; 9606.ENSP00000365380; -.
DR   iPTMnet; Q9BZS1; -.
DR   PhosphoSitePlus; Q9BZS1; -.
DR   SwissPalm; Q9BZS1; -.
DR   BioMuta; FOXP3; -.
DR   DMDM; 14548061; -.
DR   MaxQB; Q9BZS1; -.
DR   PaxDb; Q9BZS1; -.
DR   PeptideAtlas; Q9BZS1; -.
DR   PRIDE; Q9BZS1; -.
DR   TopDownProteomics; Q9BZS1-3; -. [Q9BZS1-3]
DR   DNASU; 50943; -.
DR   Ensembl; ENST00000376199; ENSP00000365372; ENSG00000049768. [Q9BZS1-2]
DR   Ensembl; ENST00000376207; ENSP00000365380; ENSG00000049768. [Q9BZS1-1]
DR   Ensembl; ENST00000518685; ENSP00000428952; ENSG00000049768. [Q9BZS1-2]
DR   Ensembl; ENST00000557224; ENSP00000451208; ENSG00000049768. [Q9BZS1-3]
DR   GeneID; 50943; -.
DR   KEGG; hsa:50943; -.
DR   UCSC; uc004dne.5; human. [Q9BZS1-1]
DR   CTD; 50943; -.
DR   DisGeNET; 50943; -.
DR   GeneCards; FOXP3; -.
DR   GeneReviews; FOXP3; -.
DR   HGNC; HGNC:6106; FOXP3.
DR   HPA; CAB026301; -.
DR   HPA; HPA045943; -.
DR   MalaCards; FOXP3; -.
DR   MIM; 300292; gene.
DR   MIM; 304790; phenotype.
DR   neXtProt; NX_Q9BZS1; -.
DR   OpenTargets; ENSG00000049768; -.
DR   Orphanet; 37042; Immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome.
DR   PharmGKB; PA201094; -.
DR   eggNOG; KOG4385; Eukaryota.
DR   eggNOG; COG5025; LUCA.
DR   GeneTree; ENSGT00800000124014; -.
DR   HOGENOM; HOG000082490; -.
DR   HOVERGEN; HBG051656; -.
DR   InParanoid; Q9BZS1; -.
DR   KO; K10163; -.
DR   OMA; DSPAMIS; -.
DR   OrthoDB; EOG091G08HY; -.
DR   PhylomeDB; Q9BZS1; -.
DR   TreeFam; TF326978; -.
DR   SignaLink; Q9BZS1; -.
DR   SIGNOR; Q9BZS1; -.
DR   EvolutionaryTrace; Q9BZS1; -.
DR   GeneWiki; FOXP3; -.
DR   GenomeRNAi; 50943; -.
DR   PRO; PR:Q9BZS1; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000049768; -.
DR   CleanEx; HS_FOXP3; -.
DR   ExpressionAtlas; Q9BZS1; baseline and differential.
DR   Genevisible; Q9BZS1; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; NAS:UniProtKB.
DR   GO; GO:0001047; F:core promoter binding; ISS:UniProtKB.
DR   GO; GO:0035035; F:histone acetyltransferase binding; IPI:BHF-UCL.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0051059; F:NF-kappaB binding; NAS:UniProtKB.
DR   GO; GO:0051525; F:NFAT protein binding; IPI:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0000981; F:RNA polymerase II transcription factor activity, sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:Ensembl.
DR   GO; GO:0003705; F:transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding; IEA:Ensembl.
DR   GO; GO:0003700; F:transcription factor activity, sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; IBA:GO_Central.
DR   GO; GO:0001782; P:B cell homeostasis; IEA:Ensembl.
DR   GO; GO:0002362; P:CD4-positive, CD25-positive, alpha-beta regulatory T cell lineage commitment; TAS:UniProtKB.
DR   GO; GO:0006338; P:chromatin remodeling; NAS:UniProtKB.
DR   GO; GO:0001816; P:cytokine production; IEA:Ensembl.
DR   GO; GO:0002262; P:myeloid cell homeostasis; IEA:Ensembl.
DR   GO; GO:0046007; P:negative regulation of activated T cell proliferation; NAS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0002677; P:negative regulation of chronic inflammatory response; IEA:Ensembl.
DR   GO; GO:0032792; P:negative regulation of CREB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0042036; P:negative regulation of cytokine biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0050710; P:negative regulation of cytokine secretion; IDA:UniProtKB.
DR   GO; GO:0035067; P:negative regulation of histone acetylation; IEA:Ensembl.
DR   GO; GO:0031064; P:negative regulation of histone deacetylation; IGI:BHF-UCL.
DR   GO; GO:0050777; P:negative regulation of immune response; IDA:UniProtKB.
DR   GO; GO:0045077; P:negative regulation of interferon-gamma biosynthetic process; IEA:Ensembl.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IDA:UniProtKB.
DR   GO; GO:0032693; P:negative regulation of interleukin-10 production; IDA:UniProtKB.
DR   GO; GO:0032700; P:negative regulation of interleukin-17 production; IMP:UniProtKB.
DR   GO; GO:0045085; P:negative regulation of interleukin-2 biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; IDA:UniProtKB.
DR   GO; GO:0032713; P:negative regulation of interleukin-4 production; IDA:UniProtKB.
DR   GO; GO:0032714; P:negative regulation of interleukin-5 production; IEA:Ensembl.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0048294; P:negative regulation of isotype switching to IgE isotypes; IEA:Ensembl.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0002725; P:negative regulation of T cell cytokine production; IDA:UniProtKB.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IDA:UniProtKB.
DR   GO; GO:2000320; P:negative regulation of T-helper 17 cell differentiation; IMP:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0032831; P:positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation; TAS:UniProtKB.
DR   GO; GO:0035066; P:positive regulation of histone acetylation; IMP:BHF-UCL.
DR   GO; GO:0033092; P:positive regulation of immature T cell proliferation in thymus; IEA:Ensembl.
DR   GO; GO:0032753; P:positive regulation of interleukin-4 production; IEA:Ensembl.
DR   GO; GO:0002851; P:positive regulation of peripheral T cell tolerance induction; IEA:Ensembl.
DR   GO; GO:0002669; P:positive regulation of T cell anergy; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0032914; P:positive regulation of transforming growth factor beta1 production; IEA:Ensembl.
DR   GO; GO:0048302; P:regulation of isotype switching to IgG isotypes; IEA:Ensembl.
DR   GO; GO:0002667; P:regulation of T cell anergy; ISS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   GO; GO:0042110; P:T cell activation; IDA:UniProtKB.
DR   GO; GO:0043029; P:T cell homeostasis; NAS:UniProtKB.
DR   GO; GO:0002456; P:T cell mediated immunity; IEA:Ensembl.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0002513; P:tolerance induction to self antigen; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.10.10; -; 1.
DR   InterPro; IPR001766; Fork_head_dom.
DR   InterPro; IPR032354; FOXP-CC.
DR   InterPro; IPR030456; TF_fork_head_CS_2.
DR   InterPro; IPR011991; WHTH_DNA-bd_dom.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   Pfam; PF00250; Forkhead; 1.
DR   Pfam; PF16159; FOXP-CC; 1.
DR   PRINTS; PR00053; FORKHEAD.
DR   SMART; SM00339; FH; 1.
DR   SUPFAM; SSF46785; SSF46785; 1.
DR   PROSITE; PS00658; FORK_HEAD_2; 1.
DR   PROSITE; PS50039; FORK_HEAD_3; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Complete proteome; Cytoplasm; Diabetes mellitus; Disease mutation;
KW   DNA-binding; Isopeptide bond; Metal-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Ubl conjugation; Zinc; Zinc-finger.
FT   CHAIN         1    431       Forkhead box protein P3.
FT                                /FTId=PRO_0000091886.
FT   CHAIN         1    417       Forkhead box protein P3, C-terminally
FT                                processed. {ECO:0000305|PubMed:19117830}.
FT                                /FTId=PRO_0000432430.
FT   CHAIN        52    417       Forkhead box protein P3 41 kDa form.
FT                                {ECO:0000305|PubMed:19117830}.
FT                                /FTId=PRO_0000432431.
FT   PROPEP      418    431       {ECO:0000305|PubMed:19117830}.
FT                                /FTId=PRO_0000432432.
FT   ZN_FING     197    222       C2H2-type.
FT   DNA_BIND    337    423       Fork-head. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00089}.
FT   REGION      106    198       Interaction with ZFP90.
FT                                {ECO:0000269|PubMed:23543754}.
FT   REGION      106    190       Essential for transcriptional repressor
FT                                activity and for interaction with KAT5
FT                                and HDAC7. {ECO:0000269|PubMed:17360565}.
FT   REGION      149    199       Interaction with IKZF4.
FT                                {ECO:0000250|UniProtKB:Q99JB6}.
FT   REGION      239    260       Leucine-zipper.
FT   REGION      278    336       Interaction with RUNX1.
FT                                {ECO:0000269|PubMed:17377532}.
FT   MOTIF        68     76       Nuclear export signal.
FT                                {ECO:0000269|PubMed:22678915}.
FT   MOTIF        92     96       LXXLL motif.
FT                                {ECO:0000269|PubMed:18354202}.
FT   MOTIF       239    248       Nuclear export signal.
FT                                {ECO:0000269|PubMed:22678915}.
FT   MOTIF       414    417       Nuclear localization signal.
FT                                {ECO:0000269|PubMed:22678915}.
FT   SITE         51     52       Cleavage. {ECO:0000269|PubMed:19117830}.
FT   SITE        417    418       Cleavage; by PCSK1 or PCSK2.
FT                                {ECO:0000269|PubMed:19117830}.
FT   MOD_RES      19     19       Phosphoserine; by CDK2.
FT                                {ECO:0000250|UniProtKB:Q99JB6}.
FT   MOD_RES      31     31       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:22312127}.
FT   MOD_RES     263    263       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:22312127}.
FT   MOD_RES     268    268       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:22312127}.
FT   MOD_RES     418    418       Phosphoserine.
FT                                {ECO:0000269|PubMed:23396208}.
FT   CROSSLNK    250    250       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:Q99JB6}.
FT   CROSSLNK    252    252       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:Q99JB6}.
FT   CROSSLNK    263    263       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate.
FT                                {ECO:0000250|UniProtKB:Q99JB6}.
FT   CROSSLNK    268    268       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin);
FT                                alternate.
FT                                {ECO:0000250|UniProtKB:Q99JB6}.
FT   CROSSLNK    393    393       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT                                {ECO:0000250|UniProtKB:Q99JB6}.
FT   VAR_SEQ      72    106       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|Ref.4, ECO:0000303|Ref.7}.
FT                                /FTId=VSP_015796.
FT   VAR_SEQ     246    272       Missing (in isoform 4).
FT                                {ECO:0000303|Ref.3}.
FT                                /FTId=VSP_047859.
FT   VAR_SEQ     382    382       K -> KVSSSEVAVTGMASSAIAAQSGQAWVWAHRHIGEER
FT                                DVGCWWWLLASEVDAHLLPVPGLPQ (in isoform 3).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_036418.
FT   VARIANT     251    251       Missing (in IPEX).
FT                                {ECO:0000269|PubMed:11120765}.
FT                                /FTId=VAR_011330.
FT   VARIANT     363    363       I -> V (in IPEX).
FT                                {ECO:0000269|PubMed:11768393}.
FT                                /FTId=VAR_023569.
FT   VARIANT     371    371       F -> C (in IPEX; dbSNP:rs122467169).
FT                                {ECO:0000269|PubMed:11137992}.
FT                                /FTId=VAR_011331.
FT   VARIANT     384    384       A -> T (in IPEX; dbSNP:rs122467170).
FT                                {ECO:0000269|PubMed:11137992,
FT                                ECO:0000269|PubMed:11137993}.
FT                                /FTId=VAR_011332.
FT   VARIANT     397    397       R -> W (in IPEX; dbSNP:rs28935477).
FT                                {ECO:0000269|PubMed:11137992}.
FT                                /FTId=VAR_011333.
FT   MUTAGEN      69     69       L->A: Decrease in nuclear export; when
FT                                associated with A-71, A-74 and A-76.
FT                                {ECO:0000269|PubMed:22678915}.
FT   MUTAGEN      71     71       L->A: Decrease in nuclear export; when
FT                                associated with A-69, A-74 and A-76.
FT                                {ECO:0000269|PubMed:22678915}.
FT   MUTAGEN      74     74       L->A: Decrease in nuclear export; when
FT                                associated with A-69, A-71 and A-76.
FT                                {ECO:0000269|PubMed:22678915}.
FT   MUTAGEN      76     76       L->A: Decrease in nuclear export; when
FT                                associated with A-69, A-71 and A-74.
FT                                {ECO:0000269|PubMed:22678915}.
FT   MUTAGEN      95     96       LL->AA: Loss of interaction with RORA.
FT                                {ECO:0000269|PubMed:18354202}.
FT   MUTAGEN     242    242       L->A: Decrease in nuclear export; when
FT                                associated with A-246 and A-248.
FT                                {ECO:0000269|PubMed:22678915}.
FT   MUTAGEN     246    246       L->A: Decrease in nuclear export; when
FT                                associated with A-242 and A-248.
FT                                {ECO:0000269|PubMed:22678915}.
FT   MUTAGEN     248    248       L->A: Decrease in nuclear export; when
FT                                associated with A-242 and A-246.
FT                                {ECO:0000269|PubMed:22678915}.
FT   MUTAGEN     415    416       KK->EE: Loss of nuclear localization.
FT                                {ECO:0000269|PubMed:22678915}.
FT   MUTAGEN     418    418       S->A: Decrease in phosphorylation,
FT                                significant decrease in transcriptional
FT                                repressor activity and reduced
FT                                interaction with PP1CA, PP1CB and PP1CG.
FT                                Significant decrease in phosphorylation
FT                                and transcriptional repressor activity;
FT                                when associated with A-422.
FT                                {ECO:0000269|PubMed:23396208}.
FT   MUTAGEN     418    418       S->E: Slight increase in transcriptional
FT                                repressor activity.
FT                                {ECO:0000269|PubMed:23396208}.
FT   MUTAGEN     422    422       S->A: Significant decrease in
FT                                phosphorylation and transcriptional
FT                                repressor activity; when associated with
FT                                A-418. {ECO:0000269|PubMed:23396208}.
FT   CONFLICT     16     20       LGPSP -> MSPIS (in Ref. 7; CAA06748).
FT                                {ECO:0000305}.
FT   HELIX       342    351       {ECO:0000244|PDB:3QRF}.
FT   HELIX       360    371       {ECO:0000244|PDB:3QRF}.
FT   TURN        372    375       {ECO:0000244|PDB:3QRF}.
FT   HELIX       381    391       {ECO:0000244|PDB:3QRF}.
FT   STRAND      395    398       {ECO:0000244|PDB:3QRF}.
FT   STRAND      401    403       {ECO:0000244|PDB:3QRF}.
FT   STRAND      405    408       {ECO:0000244|PDB:3QRF}.
FT   HELIX       410    416       {ECO:0000244|PDB:3QRF}.
SQ   SEQUENCE   431 AA;  47244 MW;  91737C3CEA665A15 CRC64;
     MPNPRPGKPS APSLALGPSP GASPSWRAAP KASDLLGARG PGGTFQGRDL RGGAHASSSS
     LNPMPPSQLQ LPTLPLVMVA PSGARLGPLP HLQALLQDRP HFMHQLSTVD AHARTPVLQV
     HPLESPAMIS LTPPTTATGV FSLKARPGLP PGINVASLEW VSREPALLCT FPNPSAPRKD
     STLSAVPQSS YPLLANGVCK WPGCEKVFEE PEDFLKHCQA DHLLDEKGRA QCLLQREMVQ
     SLEQQLVLEK EKLSAMQAHL AGKMALTKAS SVASSDKGSC CIVAAGSQGP VVPAWSGPRE
     APDSLFAVRR HLWGSHGNST FPEFLHNMDY FKFHNMRPPF TYATLIRWAI LEAPEKQRTL
     NEIYHWFTRM FAFFRNHPAT WKNAIRHNLS LHKCFVRVES EKGAVWTVDE LEFRKKRSQR
     PSRCSNPTPG P
//
